Hypothesis

The metabolic improvement seen during somatopause stems not from lower circulating IGF‑1 but from a GH‑dependent re‑routing of IGF‑1 signaling from an endocrine to a muscle‑autocrine mode. High GH drives hepatic production of IGF‑binding protein‑1 (IGFBP‑1) and suppressor of cytokine signaling‑2 (SOCS2), which sequester IGF‑1 in the bloodstream and blunt its action in skeletal muscle. When GH declines with age, hepatic IGFBP‑1 and SOCS2 fall, freeing IGF‑1 to act locally in muscle where it stimulates GLUT4 translocation via an AMPK‑independent PI3K‑Akt cascade, thereby enhancing glucose uptake without raising systemic IGF‑1 levels. This shift explains why GH deficiency extends lifespan more robustly than IGF‑1 reduction and why IGF‑1 can still improve insulin sensitivity despite low circulating concentrations.

Testable Predictions

1. In aged mice, pharmacologic GH antagonism will decrease liver IGFBP‑1 and SOCS2 mRNA (measured by qPCR) while increasing IGF‑1 mRNA and protein specifically in gastrocnemius muscle, without altering serum IGF‑1.
2. Muscle‑specific IGF‑1 receptor knockout will abolish the glucose‑tolerance improvement caused by GH antagonism, whereas liver‑specific IGF‑1R knockout will have little effect.
3. Administering recombinant IGFBP‑1 to GH‑antagonized aged mice will restore circulating IGF‑1 sequestration and blunt the metabolic benefit, re‑inducing insulin resistance.
4. In post‑menopausal women, short‑term GH receptor blockade will lower serum IGFBP‑1 and SOCS2, increase intramuscular IGF‑1 (detected by microdialysis), and improve oral glucose tolerance; these changes will correlate with changes in muscle‑derived IGF‑1 rather than serum IGF‑1.

Mechanistic Rationale

GH stimulates JAK2‑STAT5 signaling in hepatocytes, driving transcription of IGFBP‑1 and SOCS2 (as shown in liver‑specific GH‑R knockout models). IGFBP‑1 binds IGF‑1 with high affinity, reducing its bioavailability. SOCS2 attenuates IGF‑1 receptor signaling downstream, creating systemic IGF‑1 resistance. When GH falls, these inhibitory proteins decline, allowing IGF‑1 produced locally by muscle (or released from the extracellular matrix) to engage IGF‑1R without competition. Muscle IGF‑1 then activates PI3K‑Akt, leading to AS160 phosphorylation and GLUT4 vesicle fusion, a pathway that can operate independently of AMPK activation. This model predicts that the beneficial metabolic phenotype of somatopause is uncoupled from circulating IGF‑1 levels, reconciling the apparent paradox that IGF‑1 is both pro‑aging (when endocrine) and insulin‑sensitizing (when paracrine).

Sex‑Specific Considerations

Women exhibit higher baseline IGFBP‑3 expression, which may modulate the GH‑IGF‑1 axis differently after menopause. The hypothesis predicts that GH antagonism will produce a larger relative drop in IGFBP‑1 in females, amplifying the muscle‑autocrine IGF‑1 signal and explaining the observed sex‑divergent response to hormone‑replacement therapy in clinical trials.

By focusing on the tissue‑specific bioavailability of IGF‑1 rather than its circulating concentration, this hypothesis offers a concrete, falsifiable framework for designing endocrine interventions that preserve insulin health while targeting aging pathways.